Načítá se...
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. METHODS: Patients were...
Uloženo v:
| Vydáno v: | Clin Mol Hepatol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Korean Association for the Study of the Liver
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946403/ https://ncbi.nlm.nih.gov/pubmed/27377910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2016.0020 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|